AlloVir (ALVR) Stock Price, News & Analysis

Company Overview

AlloVir, Inc. was a clinical-stage biotechnology company focused on developing allogeneic, or donor-derived, virus-specific T-cell therapies for patients whose immune systems are compromised and who are unable to effectively fight viral infections. Its approach was designed to restore or enhance antiviral immunity without requiring the patient to generate an effective immune response independently.

The company’s pipeline included posoleucel, also known as ALVR105, an investigational multi-virus-specific T-cell therapy targeting infections caused by adenovirus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6, BK virus and JC virus. AlloVir also evaluated other investigational cell therapies, including programs directed at respiratory viruses and SARS-CoV-2. These products were being developed for use in settings such as hematopoietic stem-cell and solid-organ transplantation, where viral infections can present serious clinical risks.

AlloVir was based in Waltham, Massachusetts, and conducted clinical development programs intended for patients in the United States and other international markets. The company was founded as ViraCyte and later operated under the AlloVir name. In 2023, AlloVir announced plans to discontinue development of its clinical programs and pursue strategic alternatives, substantially changing its status from an active clinical-stage biotechnology developer.

Key Stats

• Today's Range: $2.35 to $2.60
• 50-Day Range: $2.50 to $4.32
• 52-Week Range: $7.96 to $24.15
• Volume: 109,961 shs
• Average Volume: 15,685 shs
• Market Capitalization: $12.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 8/14/2024
• Today: 10/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALVR
• CIK: 1754068
• Web: www.allovir.com
• Phone: 617-433-2605
• Fax: N/A
• Employees: 110
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): ($20.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$190.42 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -71.03%
• Return on Assets: -61.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 86.78
• Quick Ratio: 86.78

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $29.35 per share
• Price / Book: 0.09

Miscellaneous

• Outstanding Shares: 5,043,000
• Free Float: 3,425,000
• Market Cap: $12.61 million
• Optionable: No Data
• Beta: 0.63